The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
Around the portal diseases we see much more of the ggt alkaline phosphatase things that affect the bile ducts — and so we often times with pediatric fatty liver disease will'll see elevations in the ggt alkaline phosphate not necessarily to the point of having an elevated Billy Rubin or a plumbing problem
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.